Muscle paralysis produced by botulinum toxin type A injection in treated torticollis patients compared with toxin naive individuals.
Identifieur interne : 003E29 ( PubMed/Corpus ); précédent : 003E28; suivant : 003E30Muscle paralysis produced by botulinum toxin type A injection in treated torticollis patients compared with toxin naive individuals.
Auteurs : R R Sloop ; D. Cole ; M C PatelSource :
- Movement disorders : official journal of the Movement Disorder Society [ 0885-3185 ] ; 2001.
English descriptors
- KwdEn :
- Adult, Aged, Botulinum Toxins, Type A (administration & dosage), Botulinum Toxins, Type A (adverse effects), Dose-Response Relationship, Drug, Female, Foot, Humans, Male, Middle Aged, Muscle, Skeletal (physiopathology), Neuromuscular Agents (administration & dosage), Neuromuscular Agents (adverse effects), Paralysis (chemically induced), Paralysis (diagnosis), Paralysis (physiopathology), Severity of Illness Index, Torticollis (drug therapy).
- MESH :
- chemical , administration & dosage : Botulinum Toxins, Type A, Neuromuscular Agents.
- chemical , adverse effects : Botulinum Toxins, Type A, Neuromuscular Agents.
- chemically induced : Paralysis.
- diagnosis : Paralysis.
- drug therapy : Torticollis.
- physiopathology : Muscle, Skeletal, Paralysis.
- Adult, Aged, Dose-Response Relationship, Drug, Female, Foot, Humans, Male, Middle Aged, Severity of Illness Index.
Abstract
We sought to determine whether the response to varying doses of botulinum toxin type A (BTX-A) injected in BTX-A-treated torticollis patients differed from the same injections given in toxin-naive individuals. We have developed a technique to objectively measure muscle weakness resulting from BTX injections in humans and have validated the technique in those not previously treated with BTX. We now examine BTX-A-treated torticollis patients to see if their response to BTX-A injection is similar to that of toxin-naive individuals. We injected 11 torticollis patients who had been receiving BTX-A injections with a standard 5-mouse unit (mu) dose into one extensor digitorum brevis (EDB) muscle and a varying dose into the other EDB, measuring muscle paralysis 2 weeks after the injection. Nine of the 11 patients were clinical and electrophysiologic responders. Two patients were non-responders. In the 9 responding patients the dose response curve to increasing doses of BTX-A was very similar to that seen in toxin-naive individuals. The mean muscle paralysis from the standard 5 mu dose was also similar to that previously reported in toxin-naive individuals. Torticollis patients who continue to respond clinically to BTX-A injections demonstrate essentially the same degree of muscle paralysis from the EDB injections as do subjects who have never been exposed to BTX-A.
PubMed: 11215566
Links to Exploration step
pubmed:11215566Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Muscle paralysis produced by botulinum toxin type A injection in treated torticollis patients compared with toxin naive individuals.</title><author><name sortKey="Sloop, R R" sort="Sloop, R R" uniqKey="Sloop R" first="R R" last="Sloop">R R Sloop</name><affiliation><nlm:affiliation>Department of Neurology, Loma Linda University School of Medicine, California, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Cole, D" sort="Cole, D" uniqKey="Cole D" first="D" last="Cole">D. Cole</name></author><author><name sortKey="Patel, M C" sort="Patel, M C" uniqKey="Patel M" first="M C" last="Patel">M C Patel</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2001">2001</date><idno type="RBID">pubmed:11215566</idno><idno type="pmid">11215566</idno><idno type="wicri:Area/PubMed/Corpus">003E29</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Muscle paralysis produced by botulinum toxin type A injection in treated torticollis patients compared with toxin naive individuals.</title><author><name sortKey="Sloop, R R" sort="Sloop, R R" uniqKey="Sloop R" first="R R" last="Sloop">R R Sloop</name><affiliation><nlm:affiliation>Department of Neurology, Loma Linda University School of Medicine, California, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Cole, D" sort="Cole, D" uniqKey="Cole D" first="D" last="Cole">D. Cole</name></author><author><name sortKey="Patel, M C" sort="Patel, M C" uniqKey="Patel M" first="M C" last="Patel">M C Patel</name></author></analytic><series><title level="j">Movement disorders : official journal of the Movement Disorder Society</title><idno type="ISSN">0885-3185</idno><imprint><date when="2001" type="published">2001</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult</term><term>Aged</term><term>Botulinum Toxins, Type A (administration & dosage)</term><term>Botulinum Toxins, Type A (adverse effects)</term><term>Dose-Response Relationship, Drug</term><term>Female</term><term>Foot</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Muscle, Skeletal (physiopathology)</term><term>Neuromuscular Agents (administration & dosage)</term><term>Neuromuscular Agents (adverse effects)</term><term>Paralysis (chemically induced)</term><term>Paralysis (diagnosis)</term><term>Paralysis (physiopathology)</term><term>Severity of Illness Index</term><term>Torticollis (drug therapy)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Botulinum Toxins, Type A</term><term>Neuromuscular Agents</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Botulinum Toxins, Type A</term><term>Neuromuscular Agents</term></keywords><keywords scheme="MESH" qualifier="chemically induced" xml:lang="en"><term>Paralysis</term></keywords><keywords scheme="MESH" qualifier="diagnosis" xml:lang="en"><term>Paralysis</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Torticollis</term></keywords><keywords scheme="MESH" qualifier="physiopathology" xml:lang="en"><term>Muscle, Skeletal</term><term>Paralysis</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adult</term><term>Aged</term><term>Dose-Response Relationship, Drug</term><term>Female</term><term>Foot</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Severity of Illness Index</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">We sought to determine whether the response to varying doses of botulinum toxin type A (BTX-A) injected in BTX-A-treated torticollis patients differed from the same injections given in toxin-naive individuals. We have developed a technique to objectively measure muscle weakness resulting from BTX injections in humans and have validated the technique in those not previously treated with BTX. We now examine BTX-A-treated torticollis patients to see if their response to BTX-A injection is similar to that of toxin-naive individuals. We injected 11 torticollis patients who had been receiving BTX-A injections with a standard 5-mouse unit (mu) dose into one extensor digitorum brevis (EDB) muscle and a varying dose into the other EDB, measuring muscle paralysis 2 weeks after the injection. Nine of the 11 patients were clinical and electrophysiologic responders. Two patients were non-responders. In the 9 responding patients the dose response curve to increasing doses of BTX-A was very similar to that seen in toxin-naive individuals. The mean muscle paralysis from the standard 5 mu dose was also similar to that previously reported in toxin-naive individuals. Torticollis patients who continue to respond clinically to BTX-A injections demonstrate essentially the same degree of muscle paralysis from the EDB injections as do subjects who have never been exposed to BTX-A.</div></front></TEI><pubmed><MedlineCitation Owner="NLM" Status="MEDLINE"><PMID Version="1">11215566</PMID><DateCreated><Year>2001</Year><Month>02</Month><Day>15</Day></DateCreated><DateCompleted><Year>2001</Year><Month>06</Month><Day>14</Day></DateCompleted><DateRevised><Year>2010</Year><Month>11</Month><Day>18</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0885-3185</ISSN><JournalIssue CitedMedium="Print"><Volume>16</Volume><Issue>1</Issue><PubDate><Year>2001</Year><Month>Jan</Month></PubDate></JournalIssue><Title>Movement disorders : official journal of the Movement Disorder Society</Title><ISOAbbreviation>Mov. Disord.</ISOAbbreviation></Journal><ArticleTitle>Muscle paralysis produced by botulinum toxin type A injection in treated torticollis patients compared with toxin naive individuals.</ArticleTitle><Pagination><MedlinePgn>100-5</MedlinePgn></Pagination><Abstract><AbstractText>We sought to determine whether the response to varying doses of botulinum toxin type A (BTX-A) injected in BTX-A-treated torticollis patients differed from the same injections given in toxin-naive individuals. We have developed a technique to objectively measure muscle weakness resulting from BTX injections in humans and have validated the technique in those not previously treated with BTX. We now examine BTX-A-treated torticollis patients to see if their response to BTX-A injection is similar to that of toxin-naive individuals. We injected 11 torticollis patients who had been receiving BTX-A injections with a standard 5-mouse unit (mu) dose into one extensor digitorum brevis (EDB) muscle and a varying dose into the other EDB, measuring muscle paralysis 2 weeks after the injection. Nine of the 11 patients were clinical and electrophysiologic responders. Two patients were non-responders. In the 9 responding patients the dose response curve to increasing doses of BTX-A was very similar to that seen in toxin-naive individuals. The mean muscle paralysis from the standard 5 mu dose was also similar to that previously reported in toxin-naive individuals. Torticollis patients who continue to respond clinically to BTX-A injections demonstrate essentially the same degree of muscle paralysis from the EDB injections as do subjects who have never been exposed to BTX-A.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Sloop</LastName><ForeName>R R</ForeName><Initials>RR</Initials><AffiliationInfo><Affiliation>Department of Neurology, Loma Linda University School of Medicine, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cole</LastName><ForeName>D</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Patel</LastName><ForeName>M C</ForeName><Initials>MC</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Mov Disord</MedlineTA><NlmUniqueID>8610688</NlmUniqueID><ISSNLinking>0885-3185</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D009465">Neuromuscular Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.24.69</RegistryNumber><NameOfSubstance UI="D019274">Botulinum Toxins, Type A</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000328">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000368">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D019274">Botulinum Toxins, Type A</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000008">administration & dosage</QualifierName><QualifierName MajorTopicYN="Y" UI="Q000009">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D004305">Dose-Response Relationship, Drug</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D005528">Foot</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D008875">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D018482">Muscle, Skeletal</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000503">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D009465">Neuromuscular Agents</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000008">administration & dosage</QualifierName><QualifierName MajorTopicYN="Y" UI="Q000009">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D010243">Paralysis</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000139">chemically induced</QualifierName><QualifierName MajorTopicYN="N" UI="Q000175">diagnosis</QualifierName><QualifierName MajorTopicYN="Y" UI="Q000503">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D012720">Severity of Illness Index</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D014103">Torticollis</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2001</Year><Month>2</Month><Day>24</Day><Hour>12</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2001</Year><Month>6</Month><Day>23</Day><Hour>10</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2001</Year><Month>2</Month><Day>24</Day><Hour>12</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">11215566</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/PubMed/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003E29 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 003E29 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= PubMed
|étape= Corpus
|type= RBID
|clé= pubmed:11215566
|texte= Muscle paralysis produced by botulinum toxin type A injection in treated torticollis patients compared with toxin naive individuals.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i -Sk "pubmed:11215566" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a MovDisordV3
| This area was generated with Dilib version V0.6.23. |  |